Workflow
万华化学:景气度与资产减值拖累业绩,贸易争端带来压力-20250420
600309wanhua(600309) 东方证券·2025-04-20 05:23

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance has been impacted by market conditions and asset impairment, with a reported revenue of 182 billion yuan for 2024, a year-on-year increase of 3.8%, and a net profit attributable to shareholders of 13 billion yuan, down 22.5% year-on-year. For Q1 2025, revenue was 430.68 billion yuan, a decline of 6.7% year-on-year, with a net profit of 30.8 billion yuan, down 25.9% year-on-year. The main reasons for the decline in performance are the significant price drops in key products such as pure MDI, TDI, and polyether, as well as in the petrochemical sector with MTBE and PVC. Although raw materials like pure benzene and LPG also saw price declines, the extent was smaller, leading to an overall decrease in gross margin. In Q4 2024, there was a significant improvement in the market conditions for MDI and other products, resulting in a quarterly increase in gross margin, but substantial asset impairment provisions and asset write-offs negatively affected net profit [5][10]. Financial Forecast and Investment Recommendations - The company has adjusted its sales price, sales volume, and raw material price assumptions based on macroeconomic changes. The earnings per share (EPS) forecasts for 2025 and 2026 have been revised to 4.37 yuan and 5.23 yuan respectively (previously 5.91 yuan and 6.83 yuan), with a new forecast for 2027 set at 6.40 yuan. The comparable company PE valuation for 2025 is set at 15 times, and due to the company's long-term ROE and historical growth being more prominent, a 15% valuation premium is applied, resulting in a target price of 74.29 yuan, maintaining the "Buy" rating [6]. Key Financial Information - For 2023, the company reported a revenue of 175.36 billion yuan, with a year-on-year growth of 5.9%. The projected revenues for 2024, 2025, 2026, and 2027 are 182.07 billion yuan, 210.05 billion yuan, 224.90 billion yuan, and 234.10 billion yuan respectively, with growth rates of 3.8%, 15.4%, 7.1%, and 4.1% [8]. - The net profit attributable to shareholders for 2023 was 16.82 billion yuan, with a projected decline to 13.03 billion yuan in 2024, followed by a slight recovery to 13.73 billion yuan in 2025, and further growth to 16.43 billion yuan in 2026 and 20.09 billion yuan in 2027 [8]. - The gross margin is expected to decrease from 16.8% in 2023 to 15.4% in 2025, before recovering to 17.9% by 2027 [8]. Market Performance - The company's absolute performance over the past week, month, three months, and year has been -8.65%, -19.84%, -19.85%, and -35.27% respectively. In comparison, the relative performance has been -9.24%, -13.97%, -18.81%, and -40.95% against the CSI 300 index [2]. Capital Expenditure and Market Conditions - The capital expenditure intensity has decreased, with a fixed asset increase of 20 billion yuan for the entire year of 2024 and a further increase of 18.6 billion yuan in Q1 2025, primarily from the Fujian base and Penglai project. The construction in progress has decreased from a peak of 69.7 billion yuan in Q3 2024 to 47.5 billion yuan in Q1 2025, indicating a significant reduction in capital expenditure intensity [10]. - The company faces pressure from trade disputes, particularly due to changes in US tariffs affecting global economic uncertainty, leading to further declines in oil prices and prices of most bulk chemical products. The impact of the Sino-US trade dispute may affect raw materials like ethane and LPG, although the company has long-term strategic partners in the Middle East to mitigate some of these pressures [10].